1.09k likes | 1.2k Views
Surviving Change in the 21 st Century. Florida Association of Blood Banks Annual Meeting Richard R. Gammon, MD Medical Director. Learning Objectives. Discuss past model of blood center operations Cover current challenges Give an overview of current and future opportunities .
E N D
Surviving Change in the 21st Century Florida Association of Blood Banks Annual Meeting Richard R. Gammon, MD Medical Director
Learning Objectives Discuss past model of blood center operations Cover current challenges Give an overview of current and future opportunities
Ancient Times • Prehistoric man • Left drawings of himself pierced by arrows • Aware of blood • Fearful as life flowed red out of body of animal or enemy Cave of Lascaux Rossi’s Principles of Transfusion Medicine. 2009
Blood has Mystical Qualities • Romans • Fountain of youth • Medea prepares cauldron of sacrificed black sheep • Gives to Jason’s father Aeson • His hair and beard…assumed the blackness of youth…limbs of vigour and robustness Bullfinch’s Mythology
Middle Ages • 1492 Pope Innocent VIII on deathbed • Physician used blood drawn from three boys 10 years of age to save life • All died-no blood received
First Animal-to-Human Transfusion • June 15, 1667 • Jean Baptiste Denis • Blood of lamb administered to 15 year-old boy – less impurities • Boy had fever and lethargy • Symptoms relieved by transfusion of 9 oz of blood
Denis’ Experience • Performed transfusions on 3 additional patients • Number 2 survived, but 3 and 4 did not • Patient 4 – 34 year-old Anthony du Mauroy • Experienced bouts of maniacal behavior • Transfused blood of a calf two times
The Fate of Mr. du Mauroy Two months later he began to experience maniacal behavior Wife sought transfusion therapy Transfusion could not be accomplished and patient died the next day Wife tried to extort money from Denis or threatened a malpractice lawsuit Denis refused and an investigation was launched
…and the Answer Is? • Madame du Mauroy had poisoned her husband with arsenic • Judgment April 17, 1668 • Denis was exonerated • Madame du Mauroy was held for trial • Transfusion should not be performed unless approved by the Physicians of the Parisian Faculty
1700s-Early 1800s • Within 10 years transfusion banned from England and France • Leeches for phlebotomy common • Contributed to death of George Washington Death of Washington by Howard Pyle
The Beginnings • Early 1800s • James Blundell • London obstetrician • Noted frequency of death after delivery
The Beginnings • Performed 10 transfusions • 5 were successful • Developed devices to facilitate transfusion • Against animal transfusions Blundell’s Gravitator
The Victorian Era • Media used for transfusion • Milk • Cows • Goats • Human milk • Abandoned when saline became available Adler J. 1892
Era of Modern Blood Banking • 1900 • Karl Landsteiner discovered ABO System • 1913 • Reuben Ottenberg • Describes compatibility testing • O as “universal” Dr. Landsteiner
Wars and Technology • Anticoagulants • Sodium citrate - WW I • ACD - WW II • Indirect transfusion -- WWII • Blood collected now • Transfused later Soldier Receives Transfusion
Wars and Technology – WW I Battlefield Blood Bank
Transfusion WW I Blood Brothers- L'Illustration – 11/21/1914
War and Technology-World War II • US begins “Plasma for Britain” project • Dr. Charles Drew heads project • 14 million units collected by war’s end
The Rise of the Community Blood Center • 1937 Dr. Bernard Fantus established first blood storage facility • Cook County Hospital in Chicago • Blood bank • Save in one place • Obtain as needed
The Rise of the Community Blood Center • 1941 • Irwin Memorial Blood Bank opens • First US community blood bank
Blood Centers The Early Days Donor RoomLaboratory
The Creation of Components • 1960s • Move to component therapy/plastics • Allows extended storage • Multiple products from one donation
Derivative Therapy • WW II – Cohn develops cold ethanol method of plasma fractionation • Albumin, fibrinogen, globulin become available • Clotting factor concentrates • 1965 Pool discovered Factor VIII could be harvested from cryoprecipitate • Hemophiliacs benefited greatly-reduced disability
Volunteerism • 1962 • Connection made between paid donations and posttransfusion hepatitis • 1970 • 1970 January designated as National Volunteer Donor Month • US moves to all volunteer donor base
The 1980s • Discovered that HIV could be transmitted in blood – 20 month infant • Up to 1% of single-donor unit transfusions were infected with HIV • Public confidence in blood supply at all-time low • Concern with slow action by regulatory/professional associations
The late 20th/Early 21st Century • Improved testing methods • Nucleic Acid Testing Introduced • HIV (1999) • Hepatitis C (1999) • West Nile Virus (2003) • Hepatitis B (2012)
2010s • Error reduction • Barcodes/RFID • iTrace – FDA clearance 05/29/13 • Emerging pathogens • Hemovigilance • Pathogen Inactivation • Cellular Therapies • Blood management http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354186.htm 05/13
Paradigm Shift B. Grigsby ABC Meeting 08/11
Hospitals Employ More Than 259,000 Physicians, Up 31% From 2000 R Umberstock ABC Meeting 03/13
Diversification J Fredericks. ABC Meeting 03/12
Role of the Blood Center ABC Webinar 12/08/10
Cell therapy companies & their products ABC Webinar 0212 ~300 therapeutic companies with ~250 cell-based therapies in the market or in some stage of clinical development. These therapies can be roughly broken down into the following stages*: ~110 Phase I ~70 Phase II~30Phase III ~40 Commercial (marketed in at least one country) Only ~1/3 of the therapies currently marketed (~13) required and received regulatory approval. In contrast, an estimated 90% of the therapies in development are “products” requiring pre-market approval. __________________________________________________________________________________ * Note that these numbers are limited to industry-sponsored trials and may not capture fully products in early-stage trials where industry “sponsorship” is less than transparent.
Have the fundamentals changed? • Cell therapy is here – instances of it being routine clinical practice & commercial • There has been incremental success • CT is now very much a part of individual, corporate, academic, policy, and financial consciousness • CT is now part of routine clinical practice and commercial products • Emerging metrics of a maturing industry (e.g., players, orgs, FDA, etc.) • On financial sector’s radar • Now working on second generation (not first generation) products. • Very little of this was true 10 year’s ago.